Our Science
The World Leader in Research and Development of nMSCs
Secretome Therapeutics is the world leader in the research and development of neonatal mesenchymal stem cells (nMSCs) for the treatment and prevention of disease. Compared to cells from donors of any other age – infants, children or adults – nMSCs display a greater capacity for healing injured or diseased tissue.
Sun et. al., Nature Reviews Urology volume 16, 2019
Mesenchymal stem cells (MSC) prevent,
treat, and reverse disease by:
Reducing inflammation
Rescuing cells from apoptosis
Stimulating mitosis
Reducing fibrosis
Restoring mitochondrial function
Enabling the repair and growth of small
blood vessels to re-supply cells with
oxygen and critical nutrients.
Recent discoveries have demonstrated that MSCs heal injured or diseased tissue primarily through the paracrine secretion of extracellular vesicles and soluble factors, which are collectively known as the cell’s secretome.
Endogenously, secretomes are the medium by which MSCs communicate to and influence other cells through the delivery of cytokines, mRNA, miRNA, and exosomes.
Secretome Therapeutics is exploiting the fact that MSCs produce different secretomes in different environments to generate a pipeline of novel secretomes that can address a wide range of diseases that are driven by the pathogenic processes that secretomes are designed to reverse.
Benefits of the Secretome
As a drug class, secretomes offer significant advantages over cell-based therapies. As living cells, MSCs are influenced by their environments, and produce different secretomes in response to different environments, potentially creating patient-to-patient variability. Secretomes are produced ex vivo in controlled conditions, enabling greater uniformity in the final drug product. Importantly, the secretome can also be concentrated several-fold greater than what cells produce naturally, making it feasible to address acute, inflammatory diseases like acute kidney injury (AKI). The secretome is also less expensive and simpler to produce, is easier to ship and store, and simpler to administer to patients compared to MSCs.
González-González et. al., World J Stem Cells. Dec 26, 2020; 12(12)
Secretome Therapeutics is exploiting the fact that MSCs produce different secretomes in different environments to generate a pipeline of novel secretomes that can address a wide range of diseases that are driven by the pathogenic processes that secretomes are designed to reverse.